carmustine

(redirected from Gliadel Wafer)
Also found in: Medical.

car·mus·tine

 (kär′mŭs-tēn′)
n.
An antineoplastic drug, C5H9Cl2N3O2, used to treat various malignancies, including Hodgkin and non-Hodgkin lymphomas, melanoma, multiple myeloma, and brain tumors.

[Probably car(bamoylation), transfer of a carbamoyl group to an amino acid (the drug's method of inhibiting certain enzymes) + mustine, an anticancer drug (must(ard) + -ine).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Eisai also gained rights to the Gliadel Wafer, a chemotherapy agent, and Dacogen for myelodysplastic syndromes.
Parikh, "Brain tumor and Gliadel wafer treatment," Indian Journal of Cancer, vol.
Having commenced fully-fledged operations earlier this year, the company has already launched the antiepileptic agent Banzel as well as the chemotherapeutic implant Gliadel Wafer for the treatment of certain malignant brain tumors.
The proprietary Gliadel wafer contains a precise amount of the chemotherapeutic drug carmustine.
Having commenced fully-fledged operations earlier this year, Eisai Canada has already launched the antiepileptic agent Banzel as well as the chemotherapeutic implant Gliadel Wafer for the treatment of certain malignant brain tumors, and has filed a New Drug Submission (NDS) with the Canadian regulatory authorities for the anticancer agent Halaven, one of Eisai's major global products.
Through MGI, Eisai also gains rights to the Gliadel Wafer, a chemotherapy agent, and Dacogen for myelodysplastic syndromes.
in which Eisai gives Norbelpharma the exclusive right to develop and commercialise GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) in Japan, while retaining an option right to obtain the exclusive commercialisation right of GLIADEL Wafer in Japan once the NDA has been filed for approval.
First, Gliadel wafers were approved by the US Food and Drug Administration in 2000 for expanded use to include intraoperative placement at the initial diagnosis of malignant brain tumor.
Gliadel Wafers are tiny discs resembling tiddlywinks which attack the cancer from close quarters.
Gliadel wafers are plastic chips, loaded with a chemotherapy medication called BCNU.
When scans showed there were cysts on his brain which had to be removed it was decided to use the opportunity to try a procedure new to Teesside - surrounding the tumour with Gliadel Wafers to attack the cancer from close quarters.
Gliadel wafers deliver carmustine directly into the tumor site.